Target Hospitality reported Q2 2025 revenue of $61.6 million, beating analyst expectations, but experienced significant profitability challenges due to terminated government contracts. The company raised full-year guidance and is focusing on diversifying revenue streams through new long-term contracts.

Bragar Eagel & Squire, P.C. is investigating potential securities law violations and other unlawful business practices by Metagenomi, Target Hospitality, Helios, and LegalZoom.

MONTRÉAL, 26 juin 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur le développement et la commercialisation de traitements innovateurs, annonce aujourd’hui que la Société dévoilera ses résultats pour le deuxième trimestre de l’exercice financier de 2024, clos le 31 mai 2024, et fera le point sur ses activités, le mercredi 10 juillet 2024, à 8 h 30 (HE).

MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its second quarter ended May 31, 2024, on Wednesday, July 10 at 8:30 a.m. ET.

Royal Caribbean (RCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

MONTREAL, May 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced Phase 1 data demonstrating signs of long-term efficacy and a manageable safety profile of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), in patients with solid tumors. The data will be presented in a poster session on June 1, 9:00 AM-12:00 PM CDT (abstract #3081, poster board #226) at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, which is taking place May 31-June 4, 2024, in Chicago, IL.

MONTRÉAL, 23 mai 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au point et la commercialisation de traitements novateurs, a annoncé aujourd’hui des données de phase I établissant des signes d’efficacité à long terme et un profil d’innocuité gérable de son principal conjugué peptide-médicament (CPM) expérimental, le sudocétaxel zendusortide (TH1902), dans le traitement de patients atteints de tumeurs solides. Les données seront présentées dans le cadre d’une séance d’affiches le 1er juin, de 9 h à 12 h (HAC) (résumé no 3081, panneau d’affichage no 226) au Congrès 2024 de l’ASCO (American Society of Clinical Oncology) qui aura lieu du 31 mai au 4 juin 2024, à Chicago (Illinois).

Royal Caribbean (RCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Target Hospitality (TH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Target Hospitality (TH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.